Mylan to launch generic EpiPen at half the price of original
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Impax Laboratories (IPXL) Issues Update on Generic Adrenaclick Auto-Injector Amid EpiPen Headlines
August 30, 2016 8:03 AM EDTImpax Laboratories, Inc. (Nasdaq: IPXL) provided an update and additional information to patients, physicians and customers on its epinephrine... More
BTIG Affirms Mylan (MYL) at 'Buy'; Generic EpiPen Highlights Challenges to U.S. Healthcare System
August 29, 2016 2:22 PM EDTBTIG affirms Mylan (Nasdaq: MYL) with a Buy rating and $60 price target as the company moves to release a generic EpiPen.
Analyst Timothy Chiang commented today, While Mylan has dealt with much criticism from the media and politicians, we believe the measures the company has announced... More
Congress Letter to FDA Questioning Generic EpiPen Alternatives (MYL) (TEVA) (ADMP) (IPXL)
August 29, 2016 1:15 PM EDTGeneric EpiPen makers are on watch after Energy and Commerce Committee leaders sent a letter to FDA Commissioner Dr. Robert Califf regarding generic drugs at FDA and ensuring we have a competitive prescription drug market.
The letter identifies a series of questions focused on the issues involved in bringing competitors to the EpiPen onto the market. The letter was sent by full committee Chairman Fred Upton... More
Generic EpiPen Pricing Parity and Less than 1% Share Supports $10 Adamis (ADMP) Target Price - Maxim Group
August 29, 2016 1:04 PM EDTAfter surging 25% on Friday as investors focused on the company's PFS an alternative to EpiPen, Adamis Pharmaceuticals (NASDAQ: ADMP) is down 15% Monday as Mylan (NYSE: MYL) announced the launch of a generic version for a list price of $300 per two-pack carton, a 50% saving.
Commenting on Adamis amid the news, Maxim Group analyst Jason Kolbert said price parity with existing generics at time of launch and modest... More
